Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456066 | 0.88 | ALDH1A1 (0.40) | ALDH1A1LMNAPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL454987 | 0.88 | ALDH1A1 (0.40) | ALDH1A1LMNAPOLBAPOBEC3AAPOBEC3G | |
| SCHEMBL24496767 | 0.88 | ALDH1A1 (0.40) | ALDH1A1LMNAPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL4419264 | 0.81 | ALDH1A1 (0.32) | ALDH1A1LMNAPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL22397290 | 0.77 | ALDH1A1 (0.34) | ALDH1A1LMNAPOLBKDM4ESMN1; SMN2 | |
| SCHEMBL15393142 | 0.74 | NFE2L2 (0.37) | — | |
| SCHEMBL719071 | 0.70 | ALDH1A1 (0.42) | ALDH1A1LMNAPOLBAPOBEC3AAPOBEC3G | |
| SCHEMBL3390915 | 0.70 | TRPA1 (0.33) | APOBEC3AAPOBEC3G | |
| SCHEMBL3390910 | 0.70 | TRPA1 (0.33) | APOBEC3AAPOBEC3G | |
| SCHEMBL19814028 | 0.68 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 850 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-14 | — | — | US | claimed |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | PROCTER & GAMBLE (US) | 2026-01-01 | — | — | US | claimed |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-30 | — | — | US | claimed |
| EP-3784707-B1 | STABLE POLYUREA MICROCAPSULE COMPOSITIONS | INT FLAVORS & FRAGRANCES INC (US) | 2025-12-24 | — | — | EP | claimed |
| US-12404479-B2 | Laundry detergent composition containing graft copolymer and benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | claimed |
| US-12384990-B2 | Treatment compositions comprising plant rosin material and certain perfume raw materials | THE PROCTER & GAMBLE COMPANY (US) | 2025-08-12 | — | — | US | claimed |
| EP-4114914-B1 | FRAGRANCE PREMIX COMPOSITIONS AND RELATED CONSUMER PRODUCTS | PROCTER & GAMBLE (US) | 2025-06-25 | — | — | EP | claimed |
| US-20250163343-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | INTERNATIONAL FLAVORES & FRAGRANCES INC. | 2025-05-22 | — | — | US | claimed |
| EP-4555060-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | The Procter & Gamble Company (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025051371-A1 | A FRAGRANCE PASTILLE | SYMRISE AG (DE) | 2025-03-13 | — | — | WO | claimed |
| WO-2022122143-A1 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| WO-2022126093-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220177813-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | claimed |
| CN-114249768-A | Phosphorus flame retardant based on amino acid and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2022-03-29 | — | — | CN | claimed |
| CN-114196475-A | Ginger flower essence | 上海应用技术大学 | 2022-03-18 | — | — | CN | claimed |
| US-20220064191-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2022-03-03 | — | — | US | claimed |
| EP-3846862-A1 | VOLATILE COMPOSITION DISPENSER | The Procter & Gamble Company (US) | 2021-07-14 | — | — | EP | claimed |
| EP-3703765-A1 | APPARATUS AND METHOD FOR REDUCING MALODOR ON SURFACES | The Procter and Gamble Company (US) | 2020-09-09 | — | — | EP | claimed |
| US-20200078486-A1 | VOLATILE COMPOSITION DISPENSER | THE PROCTER & GAMBLE COMPANY | 2020-03-12 | — | — | US | claimed |
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | HGFAC, PROKR1, FABP2 | ALDH1A1 544/4885LMNA 5/4885POLB 1543/4885 |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | ARGLU1, DAO, PNISR | ALDH1A1 4253/4885LMNA 3119/4885POLB 991/4885 |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | F2, C9, S100A8 | ALDH1A1 2233/4885LMNA 185/4885POLB 1828/4885 |
| US-20220064191-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885LMNA 87/4885POLB 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.